Lupin to acquire Amsterdam-based VISUfarma for €190M

Business Sep 29, 2025

Lupin, one of India's top pharma players, is buying Amsterdam-based VISUfarma for €190 million in a move set to wrap up by the end of 2024.
The acquisition will happen through Lupin's subsidiary Nanomi B.V., and it's all about growing Lupin's reach in Europe's booming eye-care market.

VISUfarma already sells over 60 branded products for eye health

VISUfarma already sells over 60 branded products for eye health—think treatments for dry eyes, glaucoma, and more—across countries like Italy, the UK, Spain, Germany, and France.
By bringing VISUfarma on board (using its own cash reserves), Lupin aims to boost its presence in Europe and level up its global specialty business.
CEO Vinita Gupta summed it up nicely: this move will "further build our specialty franchise in Ophthalmology."